Novavax
NVAX
389 hedge funds and large institutions have $7.69B invested in Novavax in 2021 Q1 according to their latest regulatory filings, with 103 funds opening new positions, 100 increasing their positions, 141 reducing their positions, and 58 closing their positions.
78% more capital invested
Capital invested by funds: $4.33B → $7.69B (+$3.37B)
78% more first-time investments, than exits
New positions opened: 103 | Existing positions closed: 58
12% more funds holding
Funds holding: 347 → 389 (+42)
12% more call options, than puts
Call options by funds: $893M | Put options by funds: $797M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3.41% less ownership
Funds ownership: 60.99% → 57.58% (-3.4%)
29% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 141
Top Buyers
Top Sellers
NVAX Hedge Fund Activity: Q1 2021 in Review
389 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2021, worth a combined $7.69B — up 78% from $4.33B a quarter earlier.
Buyers outnumbered sellers: 103 funds opened new NVAX positions and 58 closed out — a net gain of 45 holders — while 100 added to existing stakes and 141 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $606M. The largest seller was RA Capital Management, cutting an estimated $157M.
- 389 institutional investors held Novavax (NVAX) as of Q1 2021, up from 347 in Q4 2020.
- Funds reported $7.69B of Novavax stock for Q1 2021, up 78% quarter-over-quarter.
- 103 funds opened new Novavax positions in Q1 2021 and 58 closed out, a net change of +45 holders.
- The largest Novavax buyer in Q1 2021 was Fidelity Investments, an estimated $606M added.
- The largest Novavax seller in Q1 2021 was RA Capital Management, an estimated $157M sold.
Based on aggregated 13F filings for Q1 2021.